Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 9, 2026, 9:22 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 109 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Sublingual Buprenorphine Clear all
Not listed Phase 2 Interventional

Sublingual Buprenorphine for Chronic Pain

NCT00612287
View directory record Official record
Conditions
Chronic Pain
Interventions
buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 6, 2009 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine

NCT01366001
View directory record Official record
Conditions
Cocaine Abuse
Interventions
ALKS 33-BUP, ALKS 33, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
21 Years to 50 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2012 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional

Single Ascending Dose Study of RBP-6000

NCT03002961
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
RBP-6000, Suboxone
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Dec 25, 2016 · Synced Sep 9, 2026, 9:22 PM EDT
Terminated Phase 3 Interventional Results available

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

NCT02310581
View directory record Official record
Conditions
Post-operative Pain
Interventions
Buprenorphine Sublingual Spray, Placebo
Drug
Lead sponsor
INSYS Therapeutics Inc
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
3
States / cities
Phoenix, Arizona • Pasadena, Maryland • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 8, 2017 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Medication Maintenance Therapy in Community Pharmacy Settings

NCT03766893
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Buprenorphine / Naloxone Oral Product, injectable naltrexone, Pharmacy maintenance addiction care
Drug · Other
Lead sponsor
Lifespan
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 31, 2019 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Neurocognitive Effects of Opiate Agonist Treatment

NCT01733693
View directory record Official record
Conditions
Opioid-Related Disorders, HIV, HIV Infections
Interventions
Buprenorphine, Methadone
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 68 Years
Enrollment
135 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
2
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2022 · Synced Sep 9, 2026, 9:22 PM EDT
Withdrawn Not applicable Interventional

Can The Bridge Transition Opiate Use Disorder Patients in Stable Recovery From Buprenorphine to Naltrexone

NCT03762798
View directory record Official record
Conditions
Substance Use Disorders, Substance Abuse, Substance Use, Substance Dependence
Interventions
The Bridge
Device
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years to 99 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 22, 2021 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Extended-Release Buprenorphine vs. Sublingual Buprenorphine for the Treatment of Opioid Use Disorder

NCT04352166
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
extended-release buprenorphine (BXR), sublingual buprenorphine (BSL)
Drug
Lead sponsor
Frances R Levin
Other
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Sep 9, 2026, 9:22 PM EDT
Withdrawn Phase 4 Interventional

Comparison of Buprenorphine/Naloxone With Naltrexone in Opioid Dependent Adolescents

NCT01015066
View directory record Official record
Conditions
Opiate Addiction
Interventions
Buprenorphine/naloxone, Naltrexone
Drug
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
16 Years to 25 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

NCT02357901
View directory record Official record
Conditions
Opioid Dependence, Opioid Related Disorders
Interventions
SUBOXONE, RBP-6000, Placebo
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
665 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
38
States / cities
Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Sep 9, 2026, 9:22 PM EDT
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Low-dose Versus a High-dose Sublingual Buprenorphine Induction

NCT05944952
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
Friends Research Institute, Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Dundalk, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 11, 2025 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions

NCT00992095
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
buprenorphine hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Safety and Tolerability Study of Depot Buprenorphine in Treatment Seeking Subjects With Opioid Use Disorder

NCT02510014
View directory record Official record
Conditions
Opioid Use Disorder, Opioid-related Disorders
Interventions
SUBOXONE sublingual film, RBP-6000
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
775 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
42
States / cities
Haleyville, Alabama • Hamilton, Alabama • Little Rock, Arkansas + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 28, 2018 · Synced Sep 9, 2026, 9:22 PM EDT
Not listed Phase 1Phase 2 Interventional

Sublingual Buprenorphine Treatment for Neonatal Abstinence Syndrome - Pilot Study

NCT02249026
View directory record Official record
Conditions
Drug; Withdrawal Symptoms, Neonatal, Withdrawal, Fetus and Newborn Affected by Other Maternal Medication
Interventions
BZDs + opiate exposure treated with BPN, Opiates exposure treated with BPN
Drug
Lead sponsor
Gauda, Estelle B., M.D.
Individual
Eligibility
Up to 7 Days
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2014
U.S. locations
1
States / cities
St. Petersburg, Florida
Source: ClinicalTrials.gov public record
Updated May 5, 2016 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROL® (Naltrexone for Extended-Release Injectable Suspension)

NCT02537574
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
NTX/BUP, NTX/PBO-B, PBO-N/PBO-B
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
20
States / cities
Oceanside, California • Orange, California • Lauderhill, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2019 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional

A Six-Month Randomized Controlled Trial (RCT) of Probuphine Safety and Efficacy in Opioid Addiction

NCT01114308
View directory record Official record
Conditions
Opioid Dependency
Interventions
Probuphine (buprenorphine implant), placebo implant, Buprenorphine
Drug
Lead sponsor
Titan Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
287 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
20
States / cities
Los Angeles, California • National City, California • Oceanside, California + 16 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2018 · Synced Sep 9, 2026, 9:22 PM EDT
Withdrawn Phase 4 Interventional

Long Acting Subcutaneous vs Short Acting Sublingual Buprenorphine in Pregnant and Lactating Women

NCT04212065
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
buprenorphine
Drug
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 41 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 3 Interventional Results available

Efficacy of BNX Sublingual Tablets Versus BNX Sublingual Film for Treatment of Opioid-Dependent Adults

NCT01908842
View directory record Official record
Conditions
Opioid Dependence, on Agonist Therapy
Interventions
BNX sublingual tablets, BNX sublingual film, Buprenorphine
Drug
Lead sponsor
Orexo AB
Industry
Eligibility
18 Years to 65 Years
Enrollment
759 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
36
States / cities
Baldwin County, Alabama • Houston County, Alabama • Maricopa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated May 9, 2017 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Buprenorphine Naltrexone-P1 A-Cocaine

NCT00733720
View directory record Official record
Conditions
Cocaine-related Disorders
Interventions
Suboxone
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 55 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 11, 2017 · Synced Sep 9, 2026, 9:22 PM EDT
Terminated Phase 4 Interventional

Novel Induction to Buprenorphine/Naloxone

NCT05644587
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Use, Opioid Abuse, Opioid Misuse, Opioid Dependence
Interventions
buprenorphine/naloxone
Drug
Lead sponsor
Bicycle Health
Industry
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 19, 2024 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Medications Development for Drug Abuse Disorders

NCT01188421
View directory record Official record
Conditions
Opioid Related Disorders, Opioid Dependence, Opioid Addiction
Interventions
Buprenorphine/naloxone, Clonidine, Tramadol ER
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 60 Years
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Sep 9, 2026, 9:22 PM EDT
Recruiting Phase 4 Interventional

A Study Comparing Oral Buprenorphine and Injectable Buprenorphine for the Treatment of Opioid Use Disorder

NCT04375033
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Sublingual buprenorphine with naloxone, Injectable subcutaneous buprenorphine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
952 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
25
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Long Beach, California + 21 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2026 · Synced Sep 9, 2026, 9:22 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Buprenorphine/Naloxone Film Strips

NCT00640835
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone Film Strip
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Birmingham, Alabama • Haleyville, Alabama • Jacksonville Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced Sep 9, 2026, 9:22 PM EDT
Recruiting Phase 4 Interventional

Assessing Optimal XRB Initiation Points in Jail

NCT06051890
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Extended-Release Buprenorphine (XRB), Sublingual Buprenorphine (SLB)
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
Male only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Boston, Massachusetts • Springfield, Massachusetts • New Brunswick, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 9, 2026, 9:22 PM EDT